Background {#Sec1}
==========

The emergence of antibiotic-resistant microorganisms such as fluoroquinolone-resistant *Escherichia coli, Streptococcus pneumonia,* carbapenem-resistant *Klebsiella pneumonia*, vancomycin-resistant *enterococci* and methicillin-resistant *Staphylococcus aureus* is becoming a serious health issue worldwide. There is a critical need to develop new chemotherapeutic agents with different mechanism of action \[[@CR1]\].

Cancer is a deadly disease prevalent in both the developing as well as the developed countries. In spite of significant improvements in recognition and treatment of cancer, the incidence of certain types of malignancy is still on the rise. Current treatments such as cytotoxic chemotherapy and radiotherapy yielded only transient therapeutic aids that are accompanied by severe adverse effects. This is due to their toxic effects against normal growing cells. Concerted effort is, therefore, required to eliminate or at least reduce these incidences significantly \[[@CR2]\].

Recent findings suggest that substituted benzimidazole derivatives possess potential chemotherapeutic activity with reduced toxic effects. Antibacterial activity of substituted benzimidazole derivatives can be explained by their competition with purines, an integral part of bacterial strain, resulting in inhibition of bacterial nucleic acids and proteins synthesis \[[@CR3]\]. Compounds containing benzimidazole moiety such as thiabendazole, parbendazole, mebendazole, albendazole, cambendazole and flubendazole had also been reported for their antihelminthic activity. Similarly, the proton pump inhibitors, omeprazole, lansoprazole, rabeprazole, pantoprazole, had been reported for their use in the management of acid related disorders. In fact, benzimidazole derivatives had found their applications as antioxidant \[[@CR4]\], antimicrobial \[[@CR5]\], antihelmintic \[[@CR6]\], anticancer \[[@CR7]\], antiviral \[[@CR8]\], antiallergic \[[@CR9]\], antiarthritic \[[@CR10]\] and anti-mycobacterial agents \[[@CR11]\].

In light of above, the present study was undertaken to synthesise and evaluate the antimicrobial and anticancer potentials of substituted benzimidazole derivatives.

Results and discussion {#Sec2}
======================

Chemistry {#Sec3}
---------

Target compounds (**1**--**30**) were synthesized by following procedure outlined in Scheme [1](#Sch1){ref-type="fig"}. The physicochemical data of the target compounds are presented in Table [1](#Tab1){ref-type="table"}. The synthesized compounds were evaluated on the basis of spectral analysis: IR, NMR and Mass and elemental analyses which were in full agreement with their proposed molecular structures. The formation of Schiff bases is confirmed by the presence of N=CH str., at around 1560 cm^−1^ in the IR spectra of synthesized compounds (**1**--**11**). Asym str., at around 1550 cm^−1^ indicated the presence of aromatic nitro group in **5**, **7**, **13**, **14**, **16**, **21-28** compounds. The presence of C--O--C str., of aralkyl showed methoxy group in **3, 9, 11, 13, 17**--**20**, **27** compounds. The C--H str., at 1727 cm^−1^ confirmed the aliphatic aldehyde group in **10, 14** and **15** compounds. Furthermore, the appearance of C=O str., at 1660 cm^−1^ and the absence of NH str., of imidazole at 3400 cm^−1^ confirmed the synthesis of methanone derivatives (**12**--**30**). The multiplet corresponds to 6.697--7.823 δ ppm confirmed the presence of aromatic protons of aryl nucleus and benzimidazole. The appearance of singlet at around 9.580 δ ppm confirmed the Schiff bases (N=CH--). The singlet peak at 3.426 δ ppm indicated the presence of dimethyl group in compounds, **1, 6, 22, 29** and **30**. The doublet peak observed at 1.273--1.276 δ ppm which confirmed the presence of aliphatic methyl group in the synthesized compounds, **8**, **12** and **15**. The multiplet showed at 1.243--2.496 δ ppm confirmed the presence of CH~2~ chain of palmitoyl group in the structure of compounds (**20**, **28** and **29**). Further confirmation was made on the basis of ^13^C-NMR and MS spectral analyses. The results of C, H, N analysis are within limits of ± 0.3%.Scheme 1Synthesis of benzimidazole derivatives (**1**--**30**). Reaction condition: Step i: 2-Aminobenzimidazole, substituted aldehyde, ethanol, glacial acetic acid, reflux for 4--5 h (RT), Step ii: Schiff's base, different acylchlorides, dimethylformamide, triethylamine, stir for 24 h (RT) Table 1Physicochemical characteristic of the synthesized compoundsComp.Molecular structures with stereochemistryM. formula and CHN analysesM. wt.R*f* value% YieldM. Pt. (°C)**1**![](13065_2018_498_Stra_HTML.gif){#d29e638}*(E)*-*N*-*((E)*-*3*-*(4*-*(Dimethylamino)phenyl) allylidene)*-*1H*-*benzo\[d\]imidazol*-*2*-*amine*C~18~H~18~N~4~: Anal calcd: C, 74.46; H, 6.25; N, 19.30; Found: C, 74.43; H, 6.27; N, 19.33290.400.76^a^76228--230**2**![](13065_2018_498_Strb_HTML.gif){#d29e708}*(E)*-*1*-*(((1H*-*Benzo\[d\]imidazol*-*2*-*yl)imino)methyl)naphthalen*-*2*-*ol*C~18~H~13~N~3~O: Anal calcd: C, 75.25; H, 4.56; N, 14.63; Found: C, 75.27; H, 4.59; N, 14.60287.340.79^a^74255--257**3**![](13065_2018_498_Strc_HTML.gif){#d29e772}*(E)*-*N*-*(3,4*-*Dimethoxybenzylidene)*-*1H*-*benzo\[d\]imidazol*-*2*-*amine*C~16~H~15~N~3~O~2~: Anal calcd: C, 68.31; H, 5.37; N, 14.94; Found: C, 68.34; H, 5.35; N, 14.97281.340.77^a^78225--227**4**![](13065_2018_498_Strd_HTML.gif){#d29e839}*(E)*-*4*-*(((1H*-*Benzo\[d\]imidazol*-*2*-*yl)imino)methyl)phenol*C~14~H~11~N~3~O: Anal calcd: C, 70.87; H, 4.67; Cl, 17.71; Found: C, 70.88; H, 4.65; Cl, 17.73237.280.75^a^67220--222**5**![](13065_2018_498_Stre_HTML.gif){#d29e896}*(E)*-*N*-*(4*-*Nitrobenzylidene)*-*1H*-*benzo\[d\]imidazol*-*2*-*amine*C~14~H~10~N~4~O~2~: Anal calcd: C, 63.15; H, 3.79; N, 21.04; Found: C, 63.13; H, 3.77; N, 21.07266.280.72^a^72236--238**6**![](13065_2018_498_Strf_HTML.gif){#d29e963}(*E)*-*N*-*(4*-*(Dimethylamino)benzylidene)*-*1H*-*benzo\[d\]imidazol*-*2*-*amine*C~16~H~16~N~4~: Anal calcd: C, 72.70; H, 6.10; N, 21.20; Found: C, 72.73; H, 6.12; N, 21.22264.360.79^a^82238--240**7**![](13065_2018_498_Strg_HTML.gif){#d29e1028}*(E)*-*N*-*(3*-*Nitrobenzylidene)*-*1H*-*benzo\[d\]imidazol*-*2*-*amine*C~14~H~10~N~4~O~2~: Anal calcd: C, 63.15; H, 3.79; N, 21.04; Found: C, 63.18; H, 3.77; N, 21.05266.280.76^a^76190--192**8**![](13065_2018_498_Strh_HTML.gif){#d29e1095}*(E)*-*N*-*Ethylidene*-*1H*-*benzo\[d\]imidazol*-*2*-*amine*C~9~H~9~N~3~: Anal calcd: C, 67.90; H, 5.70; N, 26.40; Found: C, 67.88; H, 5.72; N, 26.42159.210.72^a^80172--175**9**![](13065_2018_498_Stri_HTML.gif){#d29e1158}*(E)*-*N*-*(4*-*Methoxybenzylidene)*-*1H*-*benzo\[d\]imidazol*-*2*-*amine*C~15~H~13~N~3~O: Anal calcd: C, 71.70; H, 5.21; N, 16.72; Found: C, 71.73; H, 5.22; N, 16.74251.310.71^a^75198--200**10**![](13065_2018_498_Strj_HTML.gif){#d29e1222}*(E)*-*5*-*((1H*-*Benzo\[d\]imidazol*-*2*-*yl)imino)pentanal*C~12~H~13~N~3~O: Anal calcd: C, 66.96; H, 6.09; N, 19.52; Found: C, 66.94; H, 6.11; N, 19.55215.280.75^a^78265--267**11**![](13065_2018_498_Strk_HTML.gif){#d29e1279}*(E)*-*N*-*(3,4,5*-*Trimethoxybenzylidene)*-*1H*-*benzo\[d\]imidazol*-*2*-*amine*C~17~H~17~N~3~O~3~: Anal calcd: C, 65.58; H, 5.50; N, 13.50; Found: C, 65.61; H, 5.53; N, 13.52311.370.72^a^84242--245**12**![](13065_2018_498_Strl_HTML.gif){#d29e1347}*(E)*-*1*-*(2*-*(Ethylideneamino)*-*1H*-*benzo\[d\]imidazol*-*1*-*yl)ethanone*C~11~H~11~N~3~O: Anal calcd: C, 65.66; H, 5.51; N, 20.88; Found: C, 65.65; H, 5.54; N, 20.86201.220.63^b^74262--265**13**![](13065_2018_498_Strm_HTML.gif){#d29e1411}*(E)*-*(3,5*-*Dinitrophenyl)(2*-*((4*-*methoxy*-*benzylidene)amino)*-*1H*-*benzo\[d\]imidazol*-*1*-*yl)methanone*C~22~H~15~N~5~O~6~: Anal calcd: C, 59.33; H, 3.39; N, 15.72; Found: C, 59.35; H, 3.42; N, 15.75445.380.58^b^68243--245**14**![](13065_2018_498_Strn_HTML.gif){#d29e1484}(*E)*-*5*-*((1*-*(3,5*-*Dinitrobenzoyl)*-*1H*-*benzo\[d\]imidazol*-*2*-*yl)imino)pentanal*C~14~H~11~N~3~O~2~: Anal calcd: C, 55.75; H, 3.69; N, 17.11; Found: C, 55.78; H, 3.71; N, 17.14253.260.66^b^65162--164**15**![](13065_2018_498_Stro_HTML.gif){#d29e1555}*(E)*-*5*-*((1*-*Acetyl*-*1H*-*benzo\[d\]imidazol*-*2*-*yl)imino)pentanal*C~14~H~15~N~3~O~2~: Anal calcd: C, 65.35; H, 5.88; N, 16.33; Found: C, 65.37; H, 5.90; N, 16.36257.290.62^b^72226--228**16**![](13065_2018_498_Strp_HTML.gif){#d29e1622}*(E)*-*(3,5*-*Dinitrophenyl)(2*-*((4*-*hydroxybenzylidene)amino)*-*1H*-*benzo\[d\]imidazol*-*1*-*yl)methanone*C~21~H~13~N~5~O~6~: Anal calcd: C, 58.47; H, 3.04; N, 16.24; Found: C, 58.49; H, 3.05; N, 16.25431.360.64^b^70175--177**17**![](13065_2018_498_Strq_HTML.gif){#d29e1692}(*E)*-*(2*-*((2,4*-*Dimethoxybenzylidene)amino)* -*1H*-*benzo\[d\]imidazol*-*1*-*yl)(naphthalen*-*2*-*yl)methanone*C~27~H~21~N~3~O~3~: Anal calcd: C, 74.47; H, 4.86; N, 9.65; Found: C, 74.49; H, 4.88; N, 9.68435.470.54^b^67120--122**18**![](13065_2018_498_Strr_HTML.gif){#d29e1766}*(E)*-*Naphthalen*-*2*-*yl(2*-*((3,4,5*-*trimethoxybenzylidene)amino)*-*1H*-*benzo\[d\]imidazol*-*1*-*yl)methanone*C~28~H~23~N~3~O~4~: Anal calcd: C, 72.24; H, 4.98; N, 9.03; Found: C, 72.27; H, 4.95; N, 9.05465.50.65^b^75210--212**19**![](13065_2018_498_Strs_HTML.gif){#d29e1839}*(E)*-*(3,5*-*Dinitrophenyl)(2*-*((3,4,5*-*trimethoxybenzylidene)amino)*-*1H*-*benzo\[d\]imidazol*-*1*-*yl)methanone*C~24~H~19~N~5~O~8~: Anal calcd: C, 57.03; H, 3.79; N, 13.86; Found: C, 57.07; H, 3.76; N, 13.88505.440.66^b^66141--143**20**![](13065_2018_498_Strt_HTML.gif){#d29e1909}*(E)*-*1*-*(2*-*((3,4,5*-*trimethoxybenzylidene)amino)*-*1H*-*benzo\[d\]imidazol*-*1*-*yl)hexadecan*-*1*-*one*C~33~H~47~N~3~O~4~: Anal calcd: C, 72.10; H, 8.62; N, 7.64; Found: C,72.11; H, 8.65; N, 7.67549.740.62^b^78136--138**21**![](13065_2018_498_Stru_HTML.gif){#d29e1987}*(E)*-*(3*-*Nitrophenyl)(2*-*((4*-*(pyridin*-*2*-*yl)benzylidene)amino)*-*1H*-*benzo\[d\]imidazol*-*1*-*yl)methanone*C~26~H~17~N~5~O~3~: Anal calcd: C, 69.79; H, 3.83; N, 15.65; Found: C, 69.77; H, 3.86; N, 15.68447.440.57^b^67142--144**22**![](13065_2018_498_Strv_HTML.gif){#d29e2063}*(2*-*((E)*-*((E)*-*3*-*(4*-*(Dimethylamino)phenyl) allylidene)amino)*-*1H*-*benzo\[d\]imidazol*-*1*-*yl)(3*-*nitrophenyl)methanone*C~25~H~21~N~5~O~3~: Anal calcd: C, 68.33; H, 4.82; N, 15.94; Found: C, 68.37; H, 4.80; N, 15.97439.470.59^b^82126--128**23**![](13065_2018_498_Strw_HTML.gif){#d29e2140}(*E)*-*(2*-*((4*-*(Dimethylamino)benzylidene) amino)*-*1H*-*benzo\[d\]imidazol*-*1*-*yl)(3*-*nitrophenyl)methanone*C~23~H~19~N~5~O~3~: Anal calcd: C, 66.82; H, 4.63; N, 16.94; Found: C, 66.83; H, 4.66; N, 16.97413.430.63^b^76131--133**24**![](13065_2018_498_Strx_HTML.gif){#d29e2211}*(E)*-*(2*-*(((2*-*hydroxynaphthalen*-*1*-*yl)*-*methylene)amino)*-*1H*-*benzo\[d\]imidazol*-*1*-*yl)(3*-*nitrophenyl)methanone*C~25~H~16~N~4~O~4~: Anal calcd: C, 68.80; H, 3.70; N, 12.84; Found: C, 68.83; H, 3.72; N, 12.87436.420.64^b^65134--136**25**![](13065_2018_498_Stry_HTML.gif){#d29e2290}*(E)*-*(2*-*((4*-*Nitrobenzylidene)amino)*-*1H*-*benzo\[d\]imidazol*-*1*-*yl)(3*-*nitrophenyl) methanone*C~21~H~13~N~5~O~5~: Anal calcd: C, 60.72; H, 3.15; N, 16.86; Found: C, 60.75; H, 3.17; N, 16.89415.360.66^b^74119--121**26**![](13065_2018_498_Strz_HTML.gif){#d29e2360}*(E)*-*Naphthalen*-*2*-*yl(2*-*((4*-*nitrobenzylidene)amino)*-*1H*-*benzo\[d\]imidazol*-*1*-*yl)methanone*C~25~H~16~N~4~O~3~: Anal calcd: C, 71.42; H, 3.84; N, 13.33; Found: C, 71.43; H, 3.87; N, 13.37420.420.52^b^62176--178**27**![](13065_2018_498_Straa_HTML.gif){#d29e2433}(*E)*-*(2*-*((3,4*-*Dimethoxybenzylidene)amino)* -*1H*-*benzo\[d\]imidazol*-*1*-*yl)(3*-*nitro phenyl)methanone*C~23~H~18~N~4~O~5~: Anal calcd: C, 64.18; H, 4.22; N, 13.02; Found: C, 64.21; H, 4.25; N, 13.04430.410.63^b^65235--237**28**![](13065_2018_498_Strab_HTML.gif){#d29e2504}*(E)*-*1*-*(2*-*((4*-*Nitrobenzylidene)amino)*-*1H*-*benzo\[d\]imidazol*-*1*-*yl)hexadecan*-*1*-*one*C~30~H~40~N~4~O~3~: Anal calcd: C, 71.40; H, 7.99; N, 11.10; Found: C, 71.39; H, 7.97; N, 11.12504.660.59^b^66126--128**29**![](13065_2018_498_Strac_HTML.gif){#d29e2580}*(E)*-*1*-*(2*-*((4*-*(Dimethylamino)benzylidene) amino)*-*1H*-*benzo\[d\]imidazol*-*1*-*yl)hexadecan*-*1*-*one*C~34~H~48~N~4~O: Anal calcd: C, 77.23; H, 9.15; N, 10.60; Found: C, 77.21; H, 9.16; N, 10.63528.770.64^b^68131--133**30**![](13065_2018_498_Strad_HTML.gif){#d29e2653}*(E)*-*(2*-*((4*-*(Dimethylamino)benzylidene) amino)*-*1H*-*benzo\[d\]imidazol*-*1*-*yl)(naphthalen*-*2*-*yl)methanone*C~27~H~22~N~4~O: Anal calcd: C, 77.49; H, 5.30; N, 13.39; Found: C, 77.51; H, 5.32; N, 13.42418.490.62^b^76192--195TLC mobile phase: ^a^ Ethyl acetate: Methanol (7:3); ^b^ Chloroform: Methanol (8:2)

Anticancer activity {#Sec4}
-------------------

The synthesized benzimidazole derivatives were screened for their anticancer activity against MCF7 (ATCC HTB-22), an oestrogen receptor positive human breast adeno-carcinoma cell line. Anticancer screening results (Table [2](#Tab2){ref-type="table"}) indicated that compound **22** (IC~50~ = 0.9 µM) was found to be the most potent when compared to the standard drug, 5-fluorouracil (IC~50~ = 35.4 µM). Other compounds which included **12**, **21** and **29** also exhibited more potent antiproliferative results (IC~50~ = 7.0, 5.4 and 5.5 µM, respectively) when compared to the standard drug. These compounds may be used as drug leads for discovery of new anticancer agents.Table 2Anticancer screening results of synthesized compoundsComp.MCF-7 cell lineComp.MCF-7 cell line*Anticancer screening (IC*~*50*~ = µM*)***1**31.0**16**231.8**2**41.8**17**39.0**3**170.6**18**161.1**4**101.1**19**15.8**5**67.6**20**23.6**6**\> 378.3**21**5.4**7**112.7**22**00.9**8**\> 628.1**23**50.8**9**\> 310.4**24**61.9**10**157.9**25**18.8**11**\> 321.2**26**176.0**12**7.0**27**123.1**13**19.1**28**31.7**14**\> 394.9**29**5.5**15**11.7**30**138.65-Fluorouracil35.45-Fluorouracil35.4

Antimicrobial activity {#Sec5}
----------------------

Antimicrobial activity results (Table [3](#Tab3){ref-type="table"}) indicated that the compounds possessed good antimicrobial activity against the tested bacterial and fungal strains. Compound **1** showed good antibacterial activity against *E. coli* (MIC~*ec*~ = 5.4 µM) and *B. subtilis* (MIC~*bs*~ = 10.7 µM), whereas compound **19** was found to be more potent against *S. aureus* (MIC~*sa*~= 12.4 µM). The reference drug, norfloxacin, yielded MIC of 4.7 µM against the tested microorganisms. The antifungal activity results indicated that compound **2** showed good activity against *C. albicans* (MIC~*ca*~ = 5.4 µM. Compound **19**, on the other hand, was the most potent antifungal agent against *A. niger* (MIC~*an*~ = 3.1 µM) in comparison to fluconazole (MIC = 5.0 µM), the reference drug. Thus, compound **19** may serve as a potential lead compound for the design of novel antifungal agents.Table 3Antimicrobial activity of synthesized compoundsComp.Antimicrobial screening (MIC = µM)Bacterial speciesFungal species*E. coliB. subtilisS. aureusC. albicansA. niger***1**05.410.74310.721.5**2**43.521.843.55.410.9**3**22.222.244.411.122.2**4**06.613.152.713.126.3**5**46.923.546.923.523.5**6**47.323.647.347.347.3**7**23.523.546.993.923.5**8**39.339.378.578.578.5**9**24.924.949.724.949.7**10**14.52958.12958.1**11**10.020.140.120.120.1**12**248.5248.515.562.131.1**13**56.128.114147**14**197.4197.424.798.724.7**15**194.3194.324.348.624.3**16**58.02914.514.57.2**17**28.728.714.428.77.2**18**26.913.413.426.96.7**19**49.512.412.46.23.1**20**45.511.422.722.711.4**21**27.9141455.97**22**56.928.414.228.47.1**23**60.530.215.130.27.5**24**28.628.614.328.67.1**25**60.230.11530.17.5**26**29.729.714.959.57.4**27**58.12914.5297.2**28**49.524.824.824.812.4**29**47.311.823.623.611.8**30**29.929.914.959.77.5**DMSO**NANANANANA**Std. drugs**4.7^a^4.7^a^4.7^a^5.1^b^5.1^b^*NA* no activity, *DMSO* dimethyl sulphoxideStd. drugs: ^a^ Norfloxacin, ^b^ Fluconazole

Structure activity relationship {#Sec6}
===============================

The following structure activity relationship may be drawn from the antimicrobial and anticancer activities of the benzimidazole derivatives (Fig. [1](#Fig1){ref-type="fig"}):Fig. 1Structural requirements for antimicrobial and anticancer activity of synthesized benzimidazole derivatives It has been noticed that the antibacterial activity of Schiff bases against *E. coli* enhanced due to the presence of vinyl group between benzimidazole amine and *N*-benzylidene moiety and the substitution of electron releasing group at phenyl nucleus as in the compound **1** and the same moiety improved anticancer activity of methanone derivatives as in compound **22**.The electron donating group placed at phenyl ring attached to *N*-alylidene/arylidene moiety along with presence of electron withdrawing group on phenyl ring attached to methanone moiety improved antibacterial and antifungal activity of synthesized benzimidazole derivatives against bacterial and fungal strains as in compound **19**.

Experimental {#Sec7}
============

Materials and methods {#Sec8}
---------------------

All the laboratory reagents were procured from Sigma Aldrich and were used without any purification. Melting points were determined on Sonar melting point apparatus in an open capillary tube and are uncorrected. Purity of the compound was ascertained by commercialized (E-Merck Kieselgel 60 F254) TLC plates. The Infrared spectrum was recorded in KBr discs on a Shimadzu-FTIR 8400S spectrometer (ν~max~ in cm^−1^). Proton and

^13^C NMR spectra of the synthesized compounds were recorded on Bruker Advance-II 400 NMR spectrometer with DMSO as a solvent and the chemical shift data were expressed as delta values related to tetramethylsilane. Mass spectra were recorded using Waters, Q-TOF micromass spectrometer.

### Procedure for the title compounds (**1**--**11**) {#Sec9}

2-Aminobenzimidazole (0.01 mol) was refluxed with different substituted aromatic aldehyde (0.01 mol) in ethanol (20 ml) for 4--5 h (RT) in presence of glacial acetic acid (few drops). Then the reaction mixture was allowed to cool at RT and the precipitated compound was filtered and dried \[[@CR12]\].

### Synthesis of 2-(alkyl/arylideneamino)-1H-benzo\[d\]imidazol-1-yl-alkyl/aryl-methanones (**12**--**30**) {#Sec10}

Compound of *Schiff's bases* (**1**--**11**) (0.005 mol) were stirred at RT with different acylchlorides (0.005 mol) in dimethylformamide for 24 h with the addition of small amount of triethylamine. The resulting reaction mixture was precipitated using ice cold water and the crude product was filtered through a vacuum pump, washed with cold water, dried and recrystallized using rectified spirit \[[@CR13]\].

### Spectral data of synthesized compounds {#Sec11}

#### *(E)*-*N*-*((E)*-*3*-*(4*-*(Dimethylamino)phenyl)allylidene)*-*1H*-*benzo\[d\]imidazol*-*2*-*amine* (**1**) {#FPar1}

IR (KBr cm^−1^): 1550 (N=CH str.), 3475 (N--H str.), 1431 (Ar., C=C str.), 1253 (C--N str.), 1300 (--N(CH~3~)~2~ str); ^1^H NMR (DMSO): 9.557--9.575 (d, 1H, N=CH), 6.646--6.714 (d, 1H, --CH=CH), 6.416--7.614 (m, 8H, ArH), 3.426 (s, 6H, (CH~3~)~2~); ^13^C NMR (DMSO): 40, 115, 119, 123, 127, 135, 138, 148, 159, 162; MS: *m/z* = 291.12 (M^+^ +1).

#### *(E)*-*1*-*(((1H*-*Benzo\[d\]imidazol*-*2*-*yl)imino)methyl)naphthalen*-*2*-*ol* (**2**) {#FPar2}

IR (KBr cm^−1^): 3066 (N--H str., of imidazole), 3012 (C--H aromatic ring str.), 1442 (Ar., C=C str.), 1550 (N=CH str.), 1253 (C--N str.), 3518 (O--H str.); ^1^H NMR (DMSO): 10.295 (s, 1H, N=CH), 7.096--8.108 (m, 10H, ArH), 4.481 (s, 1H, OH), 10.809 (s,1H, NH of imidazole); ^13^C NMR (DMSO): 115, 118, 123, 127, 128, 129, 132, 135, 138, 159, 162; MS: *m/z* = 288.39 (M^+^ +1).

#### *(E)*-*N*-*(3,4*-*Dimethoxybenzylidene)*-*1H*-*benzo\[d\]imidazol*-*2*-*amine* (**3**) {#FPar3}

IR (KBr cm^−1^): 3410 (N--H str.), 3058 (Ar., C--H str.), 1542 (C=C str.), 1610 (N=CH str.), 2827 (Ar., OCH~3~ str.); ^1^H NMR (DMSO): 9.487 (s, 1H, N=CH), 6.982--7.849 (m, 7H, ArH), 10.452 (s, 1H, NH of imidazole) 3.502 (s, 6H, (OCH~3~)~2~); ^13^C NMR (DMSO): 56, 115, 123, 127, 138, 152, 159, 162; MS: *m/z* = 282.14 (M^+^ +1).

#### *(E)*-*4*-*(((1H*-*Benzo\[d\]imidazol*-*2*-*yl)imino)methyl)phenol* (**4**) {#FPar4}

IR (KBr cm^−1^): 3440 (N--H str.), 3063 (Ar., C--H str.), 1537 (C=C str.), 1613 (N=CH str.), 3452 (O--H str.); ^1^H NMR (DMSO): 9.582 (s, 1H, N=CH), 7.106--8.367 (m, 8H, ArH), 10.809 (s, 1H, NH of imidazole); ^13^C NMR (DMSO): 115, 117, 123, 126, 129, 131, 138, 159, 162; MS: *m/z* = 238.17 (M^+^ +1).

#### *(E)*-*N*-*(4*-*Nitrobenzylidene)*-*1H*-*benzo\[d\]imidazol*-*2*-*amine* (**5**) {#FPar5}

IR (KBr cm^−1^): 3240 (N--H str., of imidazole ring), 2974 (C--H aromatic ring str.), 1465 (Ar., C=C str.), 1550 (N=CH str.), 1548 (Ar--C--NO~2,~ asym str.); ^1^H NMR (DMSO): 9.550 (s, 1H, N=CH), 7.103--8.105 (m, 4H, ArH), 8.116--8.376 (d, 4H, Ar-NO~2~), 12.73 (s, 1H, NH of imidazole); ^13^C NMR (DMSO): 115, 120, 123, 130, 138, 149, 159, 162; MS: *m/z* = 267.26 (M^+^ +1).

#### *(E)*-*N*-*(4*-*(Dimethylamino)benzylidene)*-*1H*-*benzo\[d\]imidazol*-*2*-*amine* (**6**) {#FPar6}

IR (KBr cm^−1^): 1550 (N=CH str.), 3374 (N--H str.), 1462 (Ar., C=C str.), 1298 (C--N str. --N(CH~3~)~2~); ^1^H NMR (DMSO): 9.206 (s, 1H, N=CH), 6.697--7.823 (m, 8H, ArH), 3.043 (s, 6H, (CH~3~)~2~), 12.42 (s, 1H, NH of imidazole); ^13^C NMR (DMSO): 40, 115, 123, 138, 159, 162; MS: *m/z* = 265.35 (M^+^ +1).

#### *(E)*-*N*-*(3*-*Nitrobenzylidene)*-*1H*-*benzo\[d\]imidazol*-*2*-*amine* (**7**) {#FPar7}

IR (KBr cm^−1^): 3428 (N--H str.), 3068 (Ar., C--H str.), 1531 (C=C str.), 1618 (C=N str.), 1547 (Ar-NO~2~ str.); ^1^H NMR (DMSO): 9.515 (s, 1H, N=CH), 7.213--8.378 (m, 8H, ArH), 10.23 (s, 1H, NH of imidazole); ^13^C NMR (DMSO): 115,123, 127, 135, 138, 150, 159, 162; MS: *m/z* = 267.28 (M^+^ +1).

#### *(E)*-*N*-*Ethylidene*-*1H*-*benzo\[d\]imidazol*-*2*-*amine* (**8**) {#FPar8}

IR (KBr cm^−1^): 3267 (N--H str., of imidazole ring), 2924 (C--H aromatic ring str.), 1465 (Ar., C=C str.), 1550 (N=CH str.), 2877 (R-CH~3~, sym str.); ^1^H NMR (DMSO): 8.654 (s, 1H, N=CH), 6.897--7.143 (m, 4H, ArH), 1.243 (s, 3H, CH~3~); ^13^C NMR: 22, 111, 120, 154, 175. MS: *m/z* = 160.28 (M^+^ +1).

#### *(E)*-*N*-*(4*-*Methoxybenzylidene)*-*1H*-*benzo\[d\]imidazol*-*2*-*amine* (**9**) {#FPar9}

IR (KBr cm^−1^): 3340 (N--H str., of imidazole ring), 2970 (C--H aromatic ring str.), 1496 (Ar., C=C str.), 1566 (N=CH str.), 1257 (C--O--C str.); ^1^H NMR (DMSO): 9.383 (s, 1H, N=CH), 7.027--7.960 (m, 8H, ArH), 3.523 (s, 3H, OCH~3~), 12.497 (s, 1H, NH of imidazole); ^13^C NMR (DMSO): 57, 114, 115, 123, 126, 130, 138, 162; MS: *m/z* = 252.28 (M^+^ +1).

#### *(E)*-*5*-*((1H*-*Benzo\[d\]imidazol*-*2*-*yl)imino)pentanal* (**10**) {#FPar10}

IR (KBr cm^−1^): 3426 (N--H str.), 3054 (Ar., C-H str.), 1562 (C=C str.), 1623 (N=CH str.), 2773 (Aliphatic C--H str.), 1724 (Aliphatic aldehyde C=O str.); ^1^H NMR (DMSO): 8.454 (t, 1H, N=CH), 6.856--7.143 (m, 4H, ArH), 1.243--2.567 (m, 6H, CH~2~), 9.700 (t, 1H, CH = O); ^13^C NMR (DMSO): 18, 28, 44, 115, 123, 138, 160, 162, 202. MS: *m/z* = 216.26 (M^+^ +1).

#### *(E)*-*N*-*(3,4,5*-*Trimethoxybenzylidene)*-*1H*-*benzo\[d\]imidazol*-*2*-*amine* (**11**) {#FPar11}

IR: 3429 (N--H str.), 3064 (Ar., C--H str.), 1577 (C=C str.), 1606 (N=CH str.), 2835 (Ar., O--CH~3~ str.); ^1^H NMR (DMSO): 9.476 (s, 1H, N=CH), 6.962--7.859 (m, 6H, ArH), 10.462 (s, 1H, NH of imidazole) 3.382 (s, 9H, (OCH~3~)~3~); ^13^C NMR (DMSO): 56, 106, 115, 123, 127, 138, 141, 152, 159, 162; MS: *m/z* = 312.14 (M^+^ +1).

#### *(E)*-*1*-*(2*-*(Ethylideneamino)*-*1H*-*benzo\[d\]imidazol*-*1*-*yl)ethanone* (**12**) {#FPar12}

IR (KBr cm^−1^): 1661 (C=O str.), 2919 (C--H aromatic str.), 1575 (N=CH str.), 2849 (CH str. (sym), R-CH~3~); ^1^H NMR (DMSO): 7.305--7.627 (m, 4H, Ar--H), 7.233 (s, 1H, N=CH), 1.273--1.276 (d, 3H, CH~3~), 2.856 (s, 3H, CH~3~); ^13^C NMR (DMSO): 16, 24, 115, 123, 129, 138, 141, 162, 168; MS: *m/z* = 201 (M^+^ +1).

#### *(E)*-*(3,5*-*Dinitrophenyl)(2*-*((4*-*methoxy*-*benzylidene)amino)*-*1H*-*benzo\[d\]imidazol*-*1*-*yl)methanone* (**13**) {#FPar13}

IR (KBr cm^−1^): 1710 (C=O str.), 2924 (C--H aromatic str.), 1537 (N=CH str.), 1545 (Ar-NO~2~ str.), 1110 (C--O--C str., OCH~3~); ^1^H NMR (DMSO): 6.785--7.943 (m, 8H, ArH), 8.632 (s, 1H, N=CH), 2.984 (s, 3H, (OCH~3~), 8.912--9.063 (m, 3H, Ar(NO~2~)~2~); ^13^C NMR (DMSO): 56, 115, 123, 125, 130, 150, 163, 168; MS: *m/z* = 445 (M^+^ +1).

#### *(E)*-*5*-*((1*-*(3,5*-*Dinitrobenzoyl)*-*1H*-*benzo\[d\]imidazol*-*2*-*yl)imino)pentanal* (**14**) {#FPar14}

IR (KBr cm^−1^): 1701 (C=O str.), 3122 (C--H aromatic str.), 1627 (N=CH str.), 1543 (Ar., NO~2~ str.), 1727 (Aliphatic aldehyde C=O str.); ^1^H NMR (DMSO): 6.875-7.946 (m, 4H, ArH), 8.632 (s, 1H, N=CH), 8.912--9.063 (m, 3H, Ar(NO~2~)~2~), 9.254--9.678 (m, 1H, CHO); ^13^C NMR (DMSO): 19, 28, 44, 115, 123, 125, 130, 150, 163, 168; MS: *m/z* = 409 (M^+^ +1).

#### *(E)*-*5*-*((1*-*Acetyl*-*1H*-*benzo\[d\]imidazol*-*2*-*yl)imino)pentanal* (**15**) {#FPar15}

IR (KBr cm^−1^): 1695 (C=O str.), 3050 (C--H aromatic str.), 1606 (N=CH str.), 1535 (C-NO~2~ str.), 2860 (C--H sym. str., R-CH~3~), 1728 (Aliphatic aldehyde C=O str.); ^1^H NMR (DMSO): 7.875--8.246 (m, 4H, ArH), 7.632 (s, 1H, N=CH), 9.254--9.678 (m, 1H, CHO), 2.856 (s, 3H, CH~3~); ^13^C NMR (DMSO): 19, 24, 28, 44, 115, 123, 138, 142, 163, 168, 202; MS: *m/z* = 257 (M^+^ +1).

#### *(E)*-*(3,5*-*Dinitrophenyl)(2*-*((4*-*hydroxybenzylidene)amino)*-*1H*-*benzo\[d\]imidazol*-*1*-*yl)methanone* (**16**) {#FPar16}

IR (KBr cm^−1^): 1685 (C=O str.), 3094 (C--H aromatic str.), 1630 (N=CH str.), 1544 (C--NO~2~ str.), 3465 (O--H str); ^1^H NMR (DMSO): 6.885--7.632 (m, 8H, ArH), 8.654 (s, 1H, N=CH), 8.912--9.063 (m, 3H, Ar (NO~2~)~2~); ^13^C NMR (DMSO): 115, 123, 125, 130, 132, 138, 150, 160, 168; MS: *m/z* = 431 (M^+^ +1).

#### *(E)*-*(2*-*((2,4*-*Dimethoxybenzylidene)amino)*-*1H*-*benzo\[d\]imidazol*-*1*-*yl)(naphthalen*-*2*-*yl)methanone* (**17**) {#FPar17}

IR (KBr cm^−1^): 1695 (C=O str.), 2919 (C--H aromatic str.), 1634 (N=CH str.), 2850 (Ar., OCH~3~ str.); 1646 (naph. ring str.); ^1^H NMR (DMSO): 6.844--8.213 (m, 14H, ArH), 8.612 (s, 1H, N=CH), 2.804 (s, 6H, (OCH~3~)~2~); ^13^C NMR (DMSO): 56, 101, 107, 109, 115, 123, 127, 129, 132, 138, 142, 160, 168; MS: *m/z* = 435 (M^+^ +1).

#### *(E)*-*Naphthalen*-*2*-*yl(2*-*((3,4,5*-*trimethoxybenzylidene)amino)*-*1H*-*benzo\[d\]imidazol*-*1*-*yl)methanone* (**18**) {#FPar18}

IR (KBr cm^−1^): 1691 (C=O str.), 1548 (N=CH str.), 1140 (C--O--C str., OCH~3~); 795 (C--H out of plane bending, naphthalene ring); ^1^H NMR (DMSO): 8.590 (s, 1H, N=CH), 4.194 (s, 9H, (OCH~3~)~3~), 6.971--8.070 (m,11H, Ar--H); ^13^C NMR (DMSO): 57, 107, 115, 123, 124, 127, 128, 131, 139, 142, 151, 160, 168; MS: *m/z* = 465 (M^+^ +1).

#### *(E)*-*(3,5*-*Dinitrophenyl)(2*-*((3,4,5*-*trimethoxybenzylidene)amino)*-*1H*-*benzo\[d\]imidazol*-*1*-*yl)methanone* (**19**) {#FPar19}

IR (KBr cm^−1^): 1681(C=O str.), 1539 (N=CH str.), 2850 (CH~3~ sym. str., R-OCH~3~); 1345 (C--NO~2~ str.); ^1^H NMR (DMSO): 8.947 (s, 1H, N=CH), 3.955 (s, 9H, (OCH~3~)~3~), 9.860--9.865 (m, 3H, Ar-(NO)~2~), 7.948--7.951 (d, 2H, Ar--H), 7.343--7.366 (m, 2H, Ar--H); ^13^C NMR (DMSO): 57, 106, 115, 125, 128, 129, 131, 139, 142, 147, 151, 168; MS: *m/z *= 505 (M^+^ +1).

#### *(E)*-*1*-*(2*-*((3,4,5*-*trimethoxybenzylidene)amino)*-*1H*-*benzo\[d\]imidazol*-*1*-*yl)hexadecan*-*1*-*one* (**20**) {#FPar20}

IR (KBr cm^−1^): 1685 (C=O str.), 3061 (C--H aromatic str.), 1623 (N=CH str.), 2843 (Ar., O--CH~3~ str.), 1266 (Palmitoyl group str.); ^1^H NMR (DMSO): 7.283--7.286 (m, 6H, ArH), 1.278--2.386 (m, 28H, CH~2~ of palmitoyl), 0.884--0.903 (t, 3H, CH~3~), 3.264 (s, 9H, (OCH~3~)~3~); ^13^C NMR (DMSO): 14, 23, 26, 30, 32, 56, 106, 115, 123, 128, 130, 139, 142, 160, 170; MS: *m/z* = 549 (M^+^ +1).

#### *(E)*-*(3*-*Nitrophenyl)(2*-*((4*-*(pyridin*-*2*-*yl)benzylidene)amino)*-*1H*-*benzo\[d\]imidazol*-*1*-*yl) methanone* (**21**) {#FPar21}

IR (KBr cm^−1^): 1682 (C=O str.), 2922 (C--H aromatic str.), 1525 (N=CH str.), 1557 (C=C and C=N str. of pyridine ring), 1543 (C--NO~2~ str.); ^1^H NMR (DMSO): 10.019 (s, 1H, N=CH), 7.305--8.658 (m, 15H, ArH), 8.662 (s, 1H, Ar--NO~2~); ^13^C NMR (DMSO): 115, 123, 126, 129, 130, 132, 142, 150, 155, 160, 168; MS: *m/z* = 447 (M^+^ +1).

#### *(2*-*((E)*-*((E)*-*3*-*(4*-*(Dimethylamino)phenyl)allylidene)amino)*-*1H*-*benzo\[d\]imidazol*-*1*-*yl)(3*-*nitrophenyl)methanone* (**22**) {#FPar22}

IR (KBr cm^−1^): 1723(C=O str.), 2920 (C--H aromatic str.), 1530 (N=CH str.), 1549 (Ar-NO~2~ str.), 1349 (C--N str., of ter. arylamine); ^1^H NMR (DMSO): 8.390--8.410 (d, 1H, N=CH), 6.731--6.740 (d, 1H, --CH = CH), 6.250--8.355 (m, 11H, ArH), 8.919 (s, 1H, Ar-NO~2~) 3.559 (s, 6H, (CH~3~)~2~); ^13^C NMR (DMSO): 40, 115, 123, 127, 131, 138, 149, 164, 168; MS: *m/z* = 439 (M^+^ +1).

#### *(E)*-*(2*-*((4*-*(Dimethylamino)benzylidene)amino)*-*1H*-*benzo\[d\]imidazol*-*1*-*yl)(3*-*nitrophenyl) methanone* (**23**) {#FPar23}

IR (KBr cm^−1^): 1719 (C=O str.), 3085 (C--H aromatic str.), 1615 (N=CH str.), 1545 (Ar-NO~2~ str.), 1514 (C--N str.); ^1^H NMR (DMSO): 7.169--8.987 (m, 12H, ArH), 9.568 (s, 1H, N=CH), 2.909 (s, 6H (CH~3~)~2~); ^13^C NMR (DMSO): 40, 115, 123, 127, 131, 138, 149, 160, 168; MS: *m/z* = 413 (M^+^ +1).

#### *(E)*-*(2*-*(((2*-*hydroxynaphthalen*-*1*-*yl)*-*methylene)amino)*-*1H*-*benzo\[d\]imidazol*-*1*-*yl)(3*-*nitrophenyl)methanone* (**24**) {#FPar24}

IR (KBr cm^−1^): 1696 (C=O str.), 2924 (C--H aromatic str.), 1553 (N=CH str.), 1546 (Ar-NO~2~ str.), 752 (O--H bending (out of plane)); ^1^H NMR (DMSO): 6.748--8.632 (m, 14H, ArH), 9.652 (s, 1H, N=CH); ^13^C NMR (DMSO):115, 118, 123, 125, 127, 128, 131, 138, 149, 160, 168; MS: *m/z* = 436 (M^+^ +1).

#### *(E)*-*(2*-*((4*-*Nitrobenzylidene)amino)*-*1H*-*benzo\[d\]imidazol*-*1*-*yl)(3*-*nitrophenyl)methanone* (**25**) {#FPar25}

IR (KBr cm^−1^): 1704 (C=O str.), 3107 (C--H aromatic str.), 1617 (N=CH str.), 1549 (Ar., NO~2~ str.); ^1^H NMR (DMSO): 7.206--8.689 (m, 12H, ArH), 9.672 (s, 1H, N=CH); ^13^C NMR (DMSO): 115, 121, 123, 125, 127, 131, 136, 139, 151, 160, 168; MS: *m/z* = 415 (M^+^ +1).

#### *(E)*-*Naphthalen*-*2*-*yl(2*-*((4*-*nitrobenzylidene)amino)*-*1H*-*benzo\[d\]imidazol*-*1*-*yl)methanone* (**26**) {#FPar26}

IR (KBr cm^−1^): 1686 (C=O str.), 3056 (C--H aromatic str.), 1600 (N=CH str.), 1545 (Ar., NO~2~ str.), 1592 (Naphthalene ring str.); ^1^H NMR (DMSO): 6.865--7.954 (m, 11H, ArH), 8.765 (s, 1H, N=CH), 8.923--8.967 (m, 4H, Ar(NO~2~); ^13^C NMR (DMSO): 115, 123, 124, 128, 129, 131, 135, 136, 139, 142, 149, 160, 168; MS: *m/z* = 420 (M^+^ +1).

#### *(E)*-*(2*-*((3,4*-*Dimethoxybenzylidene)amino)*-*1H*-*benzo\[d\]imidazol*-*1*-*yl)(3*-*nitro phenyl)methanone* (**27**) {#FPar27}

IR (KBr cm^−1^): 1684 (C=O str.), 1611 (N=CH str.), 2875 (Ar., O--CH~3~ str.); 1543 (Ar., NO~2~ str.); ^1^H NMR (DMSO): 7.463--8.932 (m, 11H, ArH), 8.185 (s, 1H, N=CH), 2.904 (s, 6H, (OCH~3~)~2~); ^13^C NMR (DMSO): 56, 115, 123, 125, 127, 136, 139, 142, 147, 150, 152, 160, 168; MS: *m/z* = 430 (M^+^ +1).

#### *(E)*-*1*-*(2*-*((4*-*Nitrobenzylidene)amino)*-*1H*-*benzo\[d\]imidazol*-*1*-*yl)hexadecan*-*1*-*one* (**28**) {#FPar28}

IR (KBr cm^−1^): 1685 (C=O str.), 2954 (C--H aromatic str.), 1618 (N=CH str.), 1271 (Palmitoyl group. str.), 1547 (Ar-NO~2~str.); ^1^H NMR (DMSO): 7.624--8.163 (m, 8H, ArH), 8.672 (s, 1H, N=CH), 1.243--2.496 (m, 28H, CH~2~ of palmitoyl), 0.845--0.878 (t, 3H, CH~3~); ^13^C NMR (DMSO): 14, 23, 26, 30, 32, 56, 106, 115, 120, 123, 125, 128, 131, 135, 136, 139, 142, 149, 160, 170; MS: *m/z* = 504 (M^+^ +1).

#### *(E)*-*1*-*(2*-*((4*-*(Dimethylamino)benzylidene)amino)*-*1H*-*benzo\[d\]imidazol*-*1*-*yl)hexadecan*-*1*-*one* (**29**) {#FPar29}

IR (KBr cm^−1^): 2927 (C--H, aromatic str.), 2813 (C--H str. aliphatic), 1659 (C=O str.), 1594 (N=CH str.), 1303 (C--N str.), 1278 (palmitoyl group str.); ^1^H NMR (DMSO): 7.878--7.901 (d, 1H, N=CH), 6.606--6.622 (d, 1H, --CH = CH), 6.661--7.519 (m, 8H, ArH), 3.773 (s, 6H, (CH~3~)~2~), 1.252--2.368 (m, 28H, CH~2~ of palmitoyl), 0.861--0.894 (t, 3H, CH~3~); ^13^C NMR (DMSO): 14, 23, 26, 30, 32, 56, 106, 115, 120, 123, 125, 128, 130, 139, 142, 149, 164, 170; MS: *m/z* = 528 (M^+^ +1).

#### *(E)*-*(2*-*((4*-*(Dimethylamino)benzylidene)amino)*-*1H*-*benzo\[d\]imidazol*-*1*-*yl)(naphthalen*-*2*-*yl)methanone* (**30**) {#FPar30}

IR (KBr cm^−1^): 1683 (C=O str.), 3054 (C--H aromatic str.), 1608 (N=CH str.), 1521 (Ar. NO~2~ str.), 1448 (C--N str.), 778 (C--H out of plane bending, naphthalene ring); ^1^H NMR (DMSO): 6.668--7.985 (m, 15H, ArH), 9.584 (s, 1H, N=CH), 2.909 (s, 6H (CH~3~)~2~); ^13^C NMR (DMSO): 40, 115, 123, 124, 128, 130, 139, 142, 160, 168; MS: *m/z* = 418 (M^+^ +1).

Biological evaluation {#Sec12}
=====================

In vitro antimicrobial assay {#Sec13}
----------------------------

Tube dilution method \[[@CR15]\] was used to determine the antimicrobial activity of synthesized compounds against Gram-positive bacteria: *Staphylococcus aureus* (MTCC-3160); *Bacillus subtilis* (MTCC-441), the Gram-negative bacterium *Escherichia coli* (MTCC-443) and fungal species: *Candida albicans* (MTCC-227) and *Aspergillus niger* (MTCC-281). Dilutions were made for test and standard compounds in appropriate double strength nutrient broth---I.P. (bacteria) or Sabouraud dextrose broth---I.P. (fungi) \[[@CR16]\]. The test and standard compounds were incubated at 37 °C for 24 h (bacteria), at 25 °C for 7 days (*A. niger*) and at 37 °C for 48 h (*C. albicans*) and the minimum inhibitory concentration (MIC) was recorded in µg/mL.

In vitro anticancer assay {#Sec14}
-------------------------

The in vitro anticancer activity of the developed compounds was performed by the Sulforhodamine B (SRB) assay as described by Skehan et al. \[[@CR14]\]. The optimal MCF-7 cell count was seeded on flat-bottom well plates and allowed to attach overnight. The compounds (20 μL) were added in quadruplicates and incubated for 72 h (both drug-free control and treated cells). Cells in each well were fixed with 200 μL of 10% cold trichloroacetic acid. After incubation for 30 min, the individual wells were rinsed with water, allowed to stain in 100 µL 0.4% SRB \[Sigma-Aldrich, St Louis, Missouri, USA\] (*w/v*; in 1% acetic acid) for 15 min. The air-dried plates were placed on a plate shaker and bound SRB was solubilised in 100 µL 10 mM Tris base solution. Absorbance was measured using a spectrophotometer at 570 nm and a dose--response curve was plotted from which the IC~50~ value of each compound against each cell type was determined.

Conclusion {#Sec15}
==========

In conclusion, a series of 1,2-disubstituted benzimidazole derivatives were synthesized and assessed for in vitro antimicrobial and anticancer activities against five representative microbial species and cancer cell line. Antimicrobial activity results indicated that the synthesized compound **1** has promising activity towards Gram negative bacteria *E. coli*. None of the compound showed more potent activity against Gram positive bacteria *B. subtilis* and *S. aureus* when compared to reference drug norfloxacin. Moreover, compounds **2** and **19** showed interesting results against fungal strains *C. albicans* and *A. niger* and comparable to fluconazole. The results from anticancer activity indicated that compounds **12**, **21**, **22** and **29** showed promising activity against MCF7. These active compounds may be taken as lead compounds for discovery of novel antimicrobial and anticancer agents in future.
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